Skip to main content

Table 3 Antimicrobial usage by SARS-COV-2 and testing status

From: A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19

Antimicrobial
n (% of total antimicrobials)
Not tested for SARS-CoV-2
(n = 452,024)
Tested for SARS-CoV-2
SARS-CoV-2 negative
(n = 124,927)
SARS-CoV-2 positive
(n = 17,049)
Total number of antimicrobialsa 225,692 (100%) 133,735 (100%) 31,981 (100%)
Antibacterial 211,088 (93.5%) 125,811 (94.1%) 29,828 (93.3%)
 Cephalosporin 61,468 (27.2%) 37,514 (28.1%) 9142 (28.6%)
  Ceftriaxone 32,198 (14.3%) 20,081 (15.0%) 5864 (18.3%)
  Cefepime 13,201 (5.8%) 10,463 (7.8%) 2647 (8.3%)
 Macrolides 14,200 (6.3%) 12,883 (9.6%) 7482 (23.4%)
  Azithromycin 13,632 (6.0%) 12,642 (9.5%) 7461 (23.4%)
 Glycopeptides 37,961 (16.8%) 23,586 (17.6%) 4254 (13.3%)
  Vancomycin 37,955 (16.8%) 23,585 (17.6%) 4254 (13.3%)
 Beta-lactam/beta-lactamase inhibitors 31,642 (14.0%) 17,997 (13.5%) 3065 (9.6%)
  Piperacillin/tazobactam 24,729 (11.0%) 14,145 (10.6%) 1981 (6.2%)
 Tetracyclines 6668 (3.0%) 5585 (4.2%) 2038 (6.4%)
 Carbapenems 7684 (3.4%) 5068 (3.8%) 1145 (3.6%)
 Fluoroquinolones 14,171 (6.3%) 7119 (5.3%) 800 (2.5%)
Antivirals 8055 (3.6%) 3918 (2.9%) 1574 (4.9%)
 Neuraminidase inhibitors 2748 (1.2%) 823 (0.6%) 950 (3.0%)
Antifungals 6549 (2.9%) 4006 (3.0%) 579 (1.8%)
  1. aPatients could have more than one prescribed antibiotic